# Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer

> **NCT01948843** · PHASE1 · COMPLETED · sponsor: **Polaris Group** · enrollment: 15 (actual)

## Conditions studied

- HER2 Negative Metastatic Breast Cancer

## Interventions

- **DRUG:** ADI-PEG 20

## Key facts

- **NCT ID:** NCT01948843
- **Lead sponsor:** Polaris Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01948843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01948843, "Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01948843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*